histidine has been researched along with mart-1 antigen in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bourseau, E; Chandrashekhar, V; Chaudhuri, A; Lafosse, S; Le Cam, E; Midoux, P; Mockey, M; Pichon, C; Quesniaux, VF; Ryffel, B | 1 |
| Baumgaertner, P; Guillaume, P; Irving, M; Luescher, IF; Schmidt, J; Speiser, D | 1 |
| Bardliving, CL; Batt, CA; Huang, CJ; Lowe, AJ; Manley, L; Old, L; Ritter, G | 1 |
3 other study(ies) available for histidine and mart-1 antigen
| Article | Year |
|---|---|
mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes.
Topics: Animals; Antigens, Neoplasm; Cancer Vaccines; Disease Progression; Histidine; MART-1 Antigen; Melanoma, Experimental; Mice; Microscopy, Electron, Transmission; Neoplasm Metastasis; Neoplasm Proteins; RNA, Messenger; T-Lymphocytes, Cytotoxic; Transcription, Genetic | 2007 |
Reversible major histocompatibility complex I-peptide multimers containing Ni(2+)-nitrilotriacetic acid peptides and histidine tags improve analysis and sorting of CD8(+) T cells.
Topics: CD8-Positive T-Lymphocytes; Histidine; HLA-A2 Antigen; Humans; MART-1 Antigen; Nickel; Nitrilotriacetic Acid; Peptides; Staining and Labeling | 2011 |
Process development and production of cGMP grade Melan-A for cancer vaccine clinical trials.
Topics: Biomedical Research; Cancer Vaccines; Chemistry, Pharmaceutical; Chromatography, Ion Exchange; Fermentation; Histidine; MART-1 Antigen; Protein Stability; Recombinant Fusion Proteins; Reproducibility of Results | 2013 |